On Friday, BTIG raised the price target for Intuitive Surgical (NASDAQ:ISRG) to $469 from $459 and reaffirmed a Buy rating on the stock. The adjustment follows Intuitive Surgical's second-quarter 2024 financial results, which revealed revenues of $2.009 billion, marking a 14.5% increase year-over-year, and an adjusted earnings per share (EPS) of $1.78.
These figures surpassed BTIG's and consensus estimates, which had anticipated revenues of $1.95 billion and an adjusted EPS of $1.52.
System sales exceeded expectations by 9.6%, and procedure volumes saw a 17.0% year-over-year growth, outpacing the Street's forecasts by 160 basis points.
A significant development in the quarter was the expansion of Intuitive Surgical's Da Vinci 5 (Dv5) install base to approximately 78 units, indicating robust demand early in the product's lifecycle. The Dv5 units accounted for about 47% of total U.S. placements during the quarter.
Management tempered expectations for the continued momentum of Dv5, noting that the supply chain is gearing up for a broader launch in the second half of 2025, along with planned hardware and software updates in the latter half of 2024.
Despite this, strong demand for the Dv5 is evident from surgeon feedback and the company's current performance.
The report also highlighted that, while procedure growth was in line with expectations and Bariatric procedures declined in the mid-single digits, Asia's market remains challenging. Nevertheless, Intuitive Surgical's adjusted gross margins and operating margins improved quarter-over-quarter by 240 basis points and 420 basis points, respectively.
This improvement suggests that the company's efforts to enhance pricing and operating efficiency are yielding results ahead of schedule, though it was noted that 50 basis points were due to one-time benefits.
Looking ahead, BTIG anticipates that Intuitive Surgical's financial metrics will continue to improve despite the various challenges and dynamics associated with the Dv5 launch. The firm expects the company to sustain demand growth and achieve greater leverage than previously projected.
In other recent news, Intuitive Surgical has been the focus of several analyst firms, each revising their price targets based on the company's recent developments. Truist Securities raised its price target to $515, citing expected revenue and EPS growth driven by the company's consistent procedure growth and anticipated new product cycle.
Similarly, Baird increased its price target to $487, highlighting the potential impact of the da Vinci 5 system on the company's future earnings. Mizuho also upped its price target to $440, reflecting positive expectations surrounding the da Vinci 5 system. Piper Sandler adjusted its price target to $490, noting strong placement numbers for the da Vinci 5 surgical robot.
In addition, the U.S. Food and Drug Administration (FDA) approved a labeling revision for Intuitive's da Vinci X and Xi surgical systems, indicating survival rates for patients undergoing robotic-assisted radical prostatectomy are comparable to those of traditional open surgery. This decision was based on a study involving nearly 25,000 patients.
InvestingPro Insights
Intuitive Surgical's recent financial performance is a testament to its growth trajectory and market confidence. In light of BTIG's updated price target and positive outlook, certain metrics from InvestingPro provide a deeper financial context. With a substantial market capitalization of $147.61 billion and a high P/E ratio of 73.62, the company is trading at a significant earnings multiple, indicating high investor expectations for future earnings. Additionally, the company's revenue growth remains strong, with a 13.81% increase over the last twelve months as of Q1 2024, showcasing its ability to expand its top line effectively.
From the perspective of InvestingPro Tips, it's notable that Intuitive Surgical is trading at a high valuation across multiple metrics, including EBITDA and revenue multiples, which may be of interest to investors considering the stock's current and future positioning. Furthermore, the company's robust liquidity position, where liquid assets exceed short-term obligations, provides financial stability and flexibility. For readers looking to delve further into the financial intricacies of Intuitive Surgical, additional InvestingPro Tips are available, which could help in making more informed investment decisions. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and gain access to the full set of 14 InvestingPro Tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.